Teva jumps as investors revisit FDA-approved PONLIMSI biosimilar catalyst ahead of earnings
Teva shares rose after the market refocused on its newly approved denosumab biosimilar PONLIMSI (Prolia reference), a March 30, 2026 FDA win that expands Teva’s biosimilar growth narrative. The move also comes as investors position ahead of Teva’s next earnings release scheduled for April 29, 2026.
1. What’s moving TEVA today
Teva Pharmaceutical Industries’ U.S.-listed shares are higher as traders rotate back into the company’s near-term biosimilar catalysts, led by PONLIMSI (denosumab-adet), Teva’s FDA-approved biosimilar referencing Amgen’s Prolia. The approval, announced March 30, 2026, positions Teva to compete in a high-volume osteoporosis market and reinforces management’s push to broaden its biosimilar portfolio.
2. Why the catalyst matters now
PONLIMSI is one of Teva’s most visible new-product levers in 2026 as investors weigh offsetting pressures from pricing and competition in legacy generics. Beyond PONLIMSI, Teva also disclosed that U.S. and European regulators accepted filings for its proposed omalizumab (Xolair reference) biosimilar, adding another pipeline milestone that can support longer-dated growth expectations.
3. Key watch items and near-term timeline
The next major scheduled checkpoint is Teva’s Q1 2026 results on April 29, 2026, which could shape expectations for 2026 cash flow, leverage reduction, and the pace of branded/biosimilar execution. Investors will also be watching for any updates on commercial readiness, competitive dynamics in denosumab, and whether legal overhangs in the category could influence launch timing and early market share.